Vancomycin Market Report 2026

Vancomycin Market Overview

• Vancomycin market size has reached to $0.91 billion in 2025 • Expected to grow to $1.46 billion in 2030 at a compound annual growth rate (CAGR) of 9.8% • Growth Driver: Impact Of Rising Infectious Disease Prevalence On The Vancomycin Market • Market Trend: Baxter International Expands Vancomycin Portfolio With New Injectable Product Launches • North America was the largest region in 2025.

What Is Covered Under Vancomycin Market?

Vancomycin is a potent antibiotic used to treat infections caused by bacteria. It belongs to the class of antibiotics known as glycopeptides and is particularly effective against Gram-positive bacteria, including strains resistant to other antibiotics. Vancomycin works by inhibiting the synthesis of the bacterial cell wall, thereby preventing the bacteria from growing and multiplying. The main types of vancomycin are injectable solution and powder for injection. Injectable solutions of vancomycin are pre-mixed liquid forms ready for intravenous administration. These solutions are used to deliver the drug directly into the bloodstream, ensuring quick and effective treatment of severe infections. The various routes of administration involved intravenous, and oral used for various applications such as sepsis, lung infection, skin soft tissue infection, colitis and intestinal inflammation, and to prevent infection.

What Is The Vancomycin Market Growth Forecast?

The vancomycin market size is expected to see strong growth in the next few years. It will grow to $1.46 billion in 2030 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to increasing demand for advanced injectable antibiotics, rising focus on infection prevention protocols, expansion of hospital pharmacy automation, growing investments in antimicrobial research, enhanced regulatory oversight on antibiotic usage. Major trends in the forecast period include increasing demand for glycopeptide antibiotics, rising focus on hospital-acquired infection management, expansion of ready-to-use injectable formulations, growing emphasis on antimicrobial stewardship programs, enhanced monitoring of drug resistance patterns.

Global Vancomycin Market Segmentation

1) By Type: Injectable Solution, Powder For Injection 2) By Route Of Administration: Intravenous, Oral 3) By Application: Sepsis, Lung Infection, Skin Soft Tissue Infection, Colitis And Intestinal Inflammation, To Prevent Infection Subsegments: 1) By Injectable Solution: Pre-Mixed Injectable Solution, Ready-To-Use Injectable Solution, Concentrated Injectable Solution 2) By Powder For Injection: Vancomycin Powder For Intravenous Use, Vancomycin Powder For Reconstitution

What Is The Driver Of The Vancomycin Market?

The rising prevalence of infectious diseases is expected to propel the growth of the vancomycin market going forward. Infectious diseases are illnesses caused by pathogenic microorganisms such as bacteria, viruses, fungi, or parasites, encompassing conditions such as influenza, tuberculosis, malaria, HIV/AIDS, and COVID-19. The increasing prevalence of infectious diseases can be attributed to factors such as antimicrobial resistance, climate change, and population growth. Vancomycin is essential for treating severe gram-positive bacterial infections, especially resistant strains, guided by clinical guidelines and antimicrobial stewardship for optimal patient outcomes. For instance, in October 2024, according to the World Health Organization, a Switzerland-based international public health organization, approximately 8.2 million people were newly diagnosed with tuberculosis in 2023, up from about 7.5 million in 2022, placing tuberculosis as the leading infectious disease killer. Therefore, the rising prevalence of infectious diseases is driving the growth of the vancomycin industry.

Key Players In The Global Vancomycin Market

Major companies operating in the vancomycin market are ANI Pharmaceuticals Inc., Alvogen Inc., Xellia Pharmaceuticals ApS, Sagent Pharmaceuticals, Fresenius Kabi AG, Lupin Limited, Eugia Pharma Specialities, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals, Slate Run Pharmaceuticals, Alkem Laboratories Ltd., Azurity Pharmaceuticals, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Novartis AG, Sanofi SA, Bayer AG, GlaxoSmithKline plc, Merck & Co Inc., Aurobindo Pharma Limited, Cipla Inc., Johnson & Johnson, Bristol‑Myers Squibb Company, AbbVie Inc., Janssen Global, Shenwei Pharmaceutical Hainan Co Ltd, Zhejiang Hisun Pharmaceutical Co Ltd, Sun Pharmaceutical Industries Ltd., Viatris Inc., North China Pharmaceutical Group, Taiwan Zhengde Pharmaceutical, LegoChem Biosciences, Nabriva Therapeutics, MicuRx Pharmaceuticals, MGB Biopharma Limited, VIANEX

Global Vancomycin Market Trends and Insights

Major companies operating in the vancomycin market are focused on developing innovative products, such as anti-infective and anti-hypotensive medications, to sustain their position in the market. Anti-infective medications are drugs used to treat infections caused by bacteria, viruses, fungi, parasites, or other microorganisms. Anti-hypotensive medications are drugs used to raise blood pressure in individuals experiencing low blood pressure (hypotension). For instance, in April 2024, Baxter International Inc., a US-based healthcare company, announced the launch of five injectable products in the US as part of its ongoing pharmaceutical portfolio growth. The new injectable products are designed to address specific medical needs, including advancements in anesthesia, pain management, and specialized therapies, reflecting the company's commitment to providing healthcare professionals with practical tools to improve patient outcomes.

What Are Latest Mergers And Acquisitions In The Vancomycin Market?

In January 2023, Fairlong Capital LLC, a US-based investment company, acquired the DoseMeRx business from Tabula Rasa HealthCare Group Inc. for an undisclosed amount. With this acquisition, Fairlong Capital LLC aims to expand its footprint in the healthcare technology sector, leveraging DoseMeRx's expertise in clinical decision support software for personalized dosing. DoseMeRx is a sophisticated tool designed for precise dosing of high-risk parenteral medications, assisting pharmacists and physicians in accurately tailoring doses according to individual patient requirements. Tabula Rasa HealthCare Group Inc. is a US-based company that provides vancomycin injections.

Regional Outlook

North America was the largest region in the vancomycin market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Vancomycin Market?

The vancomycin market consists of sales of intravenous (IV) formulations, compounded products, diagnostic kits and monitoring devices, therapeutic drug monitoring (TDM) kits, and diagnostic devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Vancomycin Market Report 2026?

The vancomycin market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the vancomycin industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.